Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials

BACKGROUND AND AIMS: Vedolizumab, a humanised monoclonal antibody for the treatment of inflammatory bowel disease, selectively blocks gut lymphocyte trafficking. This may reduce the risk of respiratory tract infections [RTIs] compared with systemic immunosuppressive therapies. To assess this possibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Feagan, Brian G, Bhayat, Fatima, Khalid, Mona, Blake, Aimee, Travis, Simon P L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065483/
https://www.ncbi.nlm.nih.gov/pubmed/29788248
http://dx.doi.org/10.1093/ecco-jcc/jjy047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065483/
https://www.ncbi.nlm.nih.gov/pubmed/29788248
http://dx.doi.org/10.1093/ecco-jcc/jjy047

Ejemplares similares